These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 17580663)
1. [Influence of long-term treatment with MPA on the biological character of endometrial carcinoma Ishikawa cell]. Zhao SJ; Chen XJ; Feng YJ Fen Zi Xi Bao Sheng Wu Xue Bao; 2007 Apr; 40(2):103-12. PubMed ID: 17580663 [TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor signaling enhanced by long-term medroxyprogesterone acetate treatment in endometrial carcinoma. Zhao S; Chen X; Lu X; Yu Y; Feng Y Gynecol Oncol; 2007 Apr; 105(1):45-54. PubMed ID: 17240435 [TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor signaling pathway involved in progestin-resistance of human endometrial carcinoma: In a mouse model. Xu Y; Tong J; Ai Z; Wang J; Teng Y J Obstet Gynaecol Res; 2012 Dec; 38(12):1358-66. PubMed ID: 22612393 [TBL] [Abstract][Full Text] [Related]
4. Response-specific progestin resistance in a newly characterized Ishikawa human endometrial cancer subcell line resulting from long-term exposure to medroxyprogesterone acetate. Zhao S; Li G; Yang L; Li L; Li H Oncol Lett; 2013 Jan; 5(1):139-144. PubMed ID: 23255909 [TBL] [Abstract][Full Text] [Related]
5. [Effect and regulation of metformin on endometrial carcinoma subline of progestin-resistance]. Niu YJ; Shi HR; Xie Y Zhonghua Fu Chan Ke Za Zhi; 2016 Feb; 51(2):135-40. PubMed ID: 26917483 [TBL] [Abstract][Full Text] [Related]
6. Progestin treatment decreases CD133+ cancer stem cell populations in endometrial cancer. Guy MS; Qamar L; Behbakht K; Post MD; Sheeder J; Sartorius CA; Spillman MA Gynecol Oncol; 2016 Mar; 140(3):518-26. PubMed ID: 26731726 [TBL] [Abstract][Full Text] [Related]
7. [Study of mechanism of medroxyprogesterone 17-acetate on the cancer stem cell-like properties of human endometrial cancer]. Liu BJ; Li XP; Zhao LJ; Wang JL; Wei LH Zhonghua Fu Chan Ke Za Zhi; 2013 Oct; 48(10):772-7. PubMed ID: 24406136 [TBL] [Abstract][Full Text] [Related]
8. Roles of SIRT1/FoxO1/SREBP-1 in the development of progestin resistance in endometrial cancer. Wang Y; Zhang L; Che X; Li W; Liu Z; Jiang J Arch Gynecol Obstet; 2018 Nov; 298(5):961-969. PubMed ID: 30206735 [TBL] [Abstract][Full Text] [Related]
9. Medroxyprogesterone acetate causes the alterations of endoplasmic reticulum related mRNAs and lncRNAs in endometrial cancer cells. Cao W; Gao W; Zheng P; Sun X; Wang L BMC Med Genomics; 2019 Nov; 12(1):163. PubMed ID: 31718641 [TBL] [Abstract][Full Text] [Related]
10. Enhanced c-jun activity alters responsiveness to medroxyprogesterone acetate in Ishikawa human endometrial carcinoma cells. Alkhalaf M; Murphy LJ; Murphy LC Mol Endocrinol; 1993 Dec; 7(12):1634-41. PubMed ID: 8145769 [TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor gene expression in human endometrial adenocarcinoma cells: regulation by progestins. Gong Y; Anzai Y; Murphy LC; Ballejo G; Holinka CF; Gurpide E; Murphy LJ Cancer Res; 1991 Oct; 51(20):5476-81. PubMed ID: 1833051 [TBL] [Abstract][Full Text] [Related]
12. 5-aza-2'-deoxycytidine improves the sensitivity of endometrial cancer cells to progesterone therapy. Hu Q; Yu L; Chen R; Wang YL; Ji L; Zhang Y; Xie Y; Liao QP Int J Gynecol Cancer; 2012 Jul; 22(6):951-9. PubMed ID: 22683940 [TBL] [Abstract][Full Text] [Related]
13. Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer. Gu C; Zhang Z; Yu Y; Liu Y; Zhao F; Yin L; Feng Y; Chen X Cancer Sci; 2011 Mar; 102(3):557-64. PubMed ID: 21205080 [TBL] [Abstract][Full Text] [Related]
14. Progestin suppresses matrix metalloproteinase production in endometrial cancer. Di Nezza LA; Jobling T; Salamonsen LA Gynecol Oncol; 2003 May; 89(2):325-33. PubMed ID: 12713999 [TBL] [Abstract][Full Text] [Related]
15. Progesterone receptor A and B expression and progestagen treatment in growth and spread of endometrial cancer cells in nude mice. Hanekamp EE; Kühne LM; Grootegoed JA; Burger CW; Blok LJ Endocr Relat Cancer; 2004 Dec; 11(4):831-41. PubMed ID: 15613456 [TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas9-Mediated Gene Knockout of ARID1A Promotes Primary Progesterone Resistance by Downregulating Progesterone Receptor B in Endometrial Cancer Cells. Wang H; Tang Z; Li T; Liu M; Li Y; Xing B Oncol Res; 2019 Sep; 27(9):1051-1060. PubMed ID: 31072420 [TBL] [Abstract][Full Text] [Related]
17. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. Xie Y; Wang YL; Yu L; Hu Q; Ji L; Zhang Y; Liao QP J Steroid Biochem Mol Biol; 2011 Sep; 126(3-5):113-20. PubMed ID: 21168492 [TBL] [Abstract][Full Text] [Related]
18. Mechanisms involved in the evolution of progestin resistance in human breast cancer cells. Murphy LC; Dotzlaw H; Wong MS; Miller T; Murphy LJ Cancer Res; 1991 Apr; 51(8):2051-7. PubMed ID: 1849041 [TBL] [Abstract][Full Text] [Related]
19. Consequences of loss of progesterone receptor expression in development of invasive endometrial cancer. Hanekamp EE; Gielen SC; Smid-Koopman E; Kühne LC; de Ruiter PE; Chadha-Ajwani S; Brinkmann AO; Grootegoed JA; Burger CW; Huikeshoven FJ; Blok LJ Clin Cancer Res; 2003 Sep; 9(11):4190-9. PubMed ID: 14519645 [TBL] [Abstract][Full Text] [Related]
20. Medroxyprogesterone acetate stimulates cdk inhibitors, p21 and p27, in endometrial carcinoma cells transfected with progesterone receptor-B cDNA. Kawaguchi M; Watanabe J; Hamano M; Kamata Y; Arai T; Nishimura Y; Obokata A; Jobo T; Kuramoto H Eur J Gynaecol Oncol; 2006; 27(1):33-8. PubMed ID: 16550965 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]